MD Virologist, My expectation is that FDA wante
Post# of 148264
My expectation is that FDA wanted a clean trial with a consistent dosing regimen and the Cytodyn did not have the standing to aggressively push for a more appropriate dosing regimen.
Upon approval physicians will invariably determine the ideal dosing and route, especially as RO and cytokine assays are brought into use.
It is encouraging to contemplate how much better leronlimab can work with ideal administration, rather than the limited dosing currently in use.